KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?

Cancer

Volumn 120, Issue 24, 2014, Pages 3862-3865

  Søreide, Kjetil ^a,b   Sandvik, Oddvar M ^a   Søreide, Jon A ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; COST BENEFIT ANALYSIS; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; LIVER RESECTION; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT SELECTION; RECURRENCE FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; COLORECTAL TUMOR; FEMALE; GENETICS; LIVER NEOPLASMS; MALE; PATHOLOGY; SECONDARY; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84918815727     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28979     Document Type: Review

References (20)

1. Nedrebo BS, Soreide K, Eriksen MT, et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. Br J Surg. 2011; 98: 716-723.
2. Nedrebo BS, Soreide K, Eriksen MT, Kvaloy JT, Soreide JA, Korner H. Excess mortality after curative surgery for colorectal cancer changes over time and differs for patients with colon versus rectal cancer. Acta Oncol. 2013; 52: 933-940.
3. Grossmann I, Doornbos PM, Klaase JM, de Bock GH, Wiggers T. Changing patterns of recurrent disease in colorectal cancer. Eur J Surg Oncol. 2014; 40: 234-239.
4. Shindoh J, Tzeng CW, Aloia TA, et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg. 2013; 100: 1777-1783.
5. Frankel TL, D'Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014; 109: 2-7.
6. Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decisionmaking on treatment strategies for colorectal liver metastases. Br J Surg. 2012; 99: 1263-1269.
7. Bischof DA, Clary BM, Maithel SK, Pawlik TM. Surgical management of disappearing colorectal liver metastases. Br J Surg. 2013; 100: 1414-1420.
8. Miranda E, Bianchi P, Destro A, et al. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer. 2013; 119: 266-276.
9. Berg M, Guriby M, Nordgard O, et al. Influence of microsatellite instability, KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. Mol Med. 2013; 19: 286-293.
10. Vermaat JS, Nijman IJ, Koudijs MJ, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 2012; 18: 688-699.
11. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010; 17: 572-578.
12. Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014; 120: 3965-3971.
13. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013; 119: 4137-4144.
14. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013; 258: 619- 626; discussion 626-627.
15. Stremitzer S, Stift J, Gruenberger B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg. 2012; 99: 1575-1582.
16. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120: 2316-2324.
17. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
18. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014; 53: 852-864.
19. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014; 15: 601-611.
20. Vauthey JN, Kopetz SE. From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer. 2013; 119: 4083-4085.